## Core Concept
The treatment of metastatic epithelial ovarian cancer often involves chemotherapy, with alkylating agents being one of the classes of drugs used. Alkylating agents work by adding an alkyl group to the DNA of cancer cells, thereby interfering with their replication and causing cell death. The effectiveness of alkylating agents in treating ovarian cancer varies depending on several factors, including the stage and histology of the cancer, as well as the patient's previous treatments.

## Why the Correct Answer is Right
The correct answer, **30-40%**, reflects the proportion of patients with metastatic epithelial ovarian cancer who can benefit from treatment with an alkylating agent. This benefit is largely seen in patients who have not received prior chemotherapy or whose cancer is sensitive to alkylating agents. The response rate to alkylating agents in ovarian cancer patients can be influenced by the presence of specific genetic mutations, such as **BRCA1** and **BRCA2** mutations, which can affect DNA repair mechanisms.

## Why Each Wrong Option is Incorrect
* **Option A (10-20%):** This option underestimates the benefit of alkylating agents in the treatment of metastatic epithelial ovarian cancer. While not all patients respond to alkylating agents, a response rate in this low range is not typical for this class of drugs in ovarian cancer.
* **Option B (50-60%):** This option overestimates the benefit. While alkylating agents are effective in a significant proportion of patients, a response rate as high as 50-60% might not accurately reflect the overall benefit seen across a broad population of patients with metastatic disease.
* **Option D (70-80%):** This option significantly overestimates the response rate to alkylating agents in patients with metastatic epithelial ovarian cancer. Such high response rates are not typically observed with alkylating agents alone in this patient population.

## Clinical Pearl / High-Yield Fact
A key point to remember is that the effectiveness of alkylating agents in ovarian cancer can be predicted by the presence of certain genetic markers and the patient's prior response to chemotherapy. Patients with **BRCA1** and **BRCA2** mutations may have a better response to certain types of chemotherapy, including alkylating agents. Additionally, the development of resistance to alkylating agents is a significant clinical challenge, and strategies to overcome resistance are an active area of research.

## Correct Answer: B. 30-40%.